NCT07060417View on ClinicalTrials.gov

Vascular Effects of SGLT2i in Non-diabetic CKD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 1, 2026

Primary Completion Date

March 31, 2029

Study Completion Date

September 30, 2029

Conditions
Non-diabetic Chronic Kidney Disease
Interventions
DRUG

Empagliflozin

Empagliflozin 10 mg, encapsulated to match the placebo, will be used.

DRUG

Placebo

Matching placebo will be used.

Trial Locations (1)

84148-0001

VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City

All Listed Sponsors
lead

VA Office of Research and Development

FED